SOPH

MKT CAP:$346M

SOPHiA GENETICS S.A.

Market Cap

$346M

Healthcare·Medical - Healthcare Information Services·🇨🇭 Switzerland·NASDAQ

Healthcare·Medical·🇨🇭·NASDAQ

Stock Price

$4.90+$0.23 (+4.93%)

Apr 24, 2026

Company Details

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalit...

CEO

Jurgi Camblong

IPO Date

Jul 23, 2021

Website

www.sophiagenetics.com

Key Metrics TTM

Revenue

$74M

+41.5% YoY

Net Income

-$82M

EPS (Diluted)

-$1.23

Free Cash Flow

-$41M

Revenue / Share

$1.09

Gross Margin

67.7%

Operating Margin

-94.8%

Net Margin

-110.3%

FCF Margin

-55.6%

P/S

4.7x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Mar 3, 2026

$77MEPS -$1.17

Q4 2025

Mar 3, 2026

$22MEPS -$0.28

Q3 2025

Nov 4, 2025

$19M+22.8%EPS -$0.30

Q3 2024

Nov 5, 2024

$16MEPS -$0.28

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 20	$7M	$5M	-$10M
Q2 20	$6M	$4M	-$7M
Q3 20	$7M	$4M	-$9M
Q2 21	$10M	$6M	-$16M
Q1 22	$11M	$7M	-$25M
Q2 22	$12M	$8M	-$24M
Q3 22	$12M	$7M	-$24M
Q1 23	$14M	$10M	-$19M
Q2 23	$15M	$10M	-$20M
Q4 23	$17M	$12M	-$19M
Q3 24	$16M	$11M	-$15M
Q3 25	$19M	$13M	-$18M
Q4 25	$22M	$15M	-$18M

Valuation

Quarter	P/S	P/E
Q1 20	—	—
Q2 20	—	—
Q3 20	—	—
Q2 21	11.3x	—
Q1 22	10.1x	—
Q2 22	8.7x	—
Q3 22	7.8x	—
Q1 23	7.2x	—
Q2 23	6.6x	—
Q4 23	6.0x	—
Q3 24	5.6x	—
Q3 25	5.1x	—
Q4 25	4.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 20	-$7M	-$8M
Q2 20	-$5M	-$6M
Q3 20	-$10M	-$11M
Q2 21	-$16M	-$18M
Q1 22	-$17M	-$20M
Q2 22	-$20M	-$22M
Q3 22	-$23M	-$25M
Q1 23	-$15M	-$17M
Q2 23	-$10M	-$13M
Q4 23	-$11M	-$14M
Q3 24	-$7M	-$9M
Q3 25	-$9M	-$9M
Q4 25	-$9M	-$9M

Capital Expenditures

Quarter	CapEx
Q1 20	$833.0K
Q2 20	$849.0K
Q3 20	$718.0K
Q2 21	$2M
Q1 22	$2M
Q2 22	$3M
Q3 22	$2M
Q1 23	$2M
Q2 23	$3M
Q4 23	$2M
Q3 24	$2M
Q3 25	$106.0K
Q4 25	$348.4K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+45.2%	+109.7%
Q2 22	+97.2%	+175.9%
Q3 22	+62.5%	+112.6%
Q1 23	+37.2%	+27.4%
Q2 23	+38.6%	-2.2%
Q4 23	+46.1%	+0.7%
Q3 24	+36.1%	-11.5%
Q3 25	+39.4%	+12.2%
Q4 25	+44.2%	+13.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 20	$270.0K	3.6%
Q2 20	$314.0K	5.3%
Q3 20	$410.0K	5.7%
Q2 21	$1M	11.8%
Q1 22	$3M	32.0%
Q2 22	$4M	33.3%
Q3 22	$4M	31.4%
Q1 23	$2M	17.4%
Q2 23	$5M	31.1%
Q4 23	$4M	24.7%
Q3 24	$4M	22.8%
Q3 25	$4M	21.3%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 20	$5M	$4M	$5M	—
Q2 20	$4M	$4M	$4M	—
Q3 20	$5M	$5M	$4M	—
Q2 21	$6M	$8M	$8M	—
Q1 22	$9M	$14M	$8M	—
Q2 22	$9M	$15M	$8M	—
Q3 22	$10M	$13M	$8M	—
Q1 23	$9M	$13M	$6M	—
Q2 23	$9M	$14M	$7M	—
Q4 23	$10M	$13M	$8M	—
Q3 24	$8M	$11M	$7M	—
Q3 25	$9M	$14M	$9M	—
Q4 25	$9M	—	—	$24M

Revenue by Geography

Quarter	Asia Pacific	Europe, The Middle East And Africa	Latin America	North America
Q2 23	$846.0K	$11M	$937.0K	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$183M	$61M	$244M
Q2 22	$179M	$38M	$217M
Q3 22	$158M	$31M	$189M
Q4 22	$161M	$17M	$179M
Q1 23	$161M	$1M	$162M
Q2 23	$149M	$0	$149M
Q3 23	$133M	$0	$133M
Q4 23	$123M	$0	$123M
Q1 24	$104M	$0	$104M
Q2 24	$105M	$0	$105M
Q3 24	$96M	$0	$96M
Q4 24	$80M	$0	$80M
Q1 25	$69M	$0	$69M
Q2 25	$95M	$0	$95M
Q3 25	$82M	$0	$82M
Q4 25	$70M	$0	$70M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 20	38M	—	—
Q2 20	48M	+25.1%	—
Q3 20	48M	0.0%	—
Q2 21	63M	+31.9%	—
Q1 22	64M	+0.9%	+66.5%
Q2 22	64M	+0.3%	+33.5%
Q3 22	64M	+0.2%	+33.7%
Q1 23	64M	+0.1%	+1.4%
Q2 23	64M	+0.4%	+1.0%
Q4 23	65M	+0.8%	+1.5%
Q3 24	66M	+2.1%	+3.4%
Q3 25	68M	+2.1%	+5.5%
Q4 25	68M	+0.7%	+5.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 20	—	—
Q2 20	—	—
Q3 20	—	—
Q2 21	—	—
Q1 22	$21.0K	518
Q2 22	$22.5K	518
Q3 22	$22.5K	518
Q1 23	$30.0K	466
Q2 23	$32.3K	466
Q4 23	$38.0K	449
Q3 24	$35.3K	449
Q3 25	$202.7K	96
Q4 25	$204.8K	106

Revenue / Employee